| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C6H4N2S4 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
FBPase-IN-1 is a potent inhibitor of FBPase (fructose-1,6-bisphosphatase) studied for Type 2 diabetes (T2D), with an IC50 of 0.22 μM. It can lower blood glucose levels and improve glucose tolerance, acting by modifying the C128 site and regulating the N125-S124-S123 allosteric pathway of FBPase, thereby affecting its catalytic activity[1]. It is supplied as a white to off-white solid (C6H4N2S4, MW 232.37) at 98.07% purity.
Physical & Chemical Properties
| CAS Number | 20362-54-3 |
|---|---|
| Molecular Formula | C6H4N2S4 |
| Molecular Weight | 232.37 g/mol |
| Purity | 98.07% |
| Appearance | Solid |
| Color | White to off-white |
| SMILES | C1(SSC2=NC=CS2)=NC=CS1 |
| Signaling Pathway | Metabolic Enzyme/Protease |
| Solubility | In Vitro: DMSO: 50 mg/mL (215.17 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | 4°C, stored under nitrogen. In solvent: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target
IC50: 0.22 μM (FBPase)[1]
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 50 mg/mL (215.17 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); stored under nitrogen; avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.5 mg/mL (10.76 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 2.5 mg/mL (10.76 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Protocol 3
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 2.5 mg/mL (10.76 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vitro
FBPase-IN-1 (1.5625-200 μM, 48 hours) shows low cytotoxicity, with an IC50 of 75.08 μM[1]. Over 0-45 min, FBPase-IN-1 inhibits FBPase in a time-dependent manner, and the IC50 decreases from 0.28 to 0.09 μM, indicating that FBPase-IN-1 is an irreversible covalent inhibitor of FBPase[1].
In Vivo
In 12 h-fasted male ICR mice (n = 6), FBPase-IN-1 (25 mg/kg, IP) shows good FBPase inhibitory activity (IC50 = 0.22 μM) and a satisfying glucose-lowering effect in vivo, with a 54% reduction in blood glucose at 25 mg/kg[1]. In male ICR mice aged 6 or 7 weeks (n = 6), a single IP dose of FBPase-IN-1 at 25 mg/kg for 4 hours lowers blood glucose levels through FBPase targeting and inhibition of the GNG process[1].
| Animal Model | ICR mouse (12 h-fasted, n = 6, male)[1] |
|---|---|
| Dosage | 25 mg/kg |
| Administration | IP, once |
| Result | Lowered glucose. |
| Animal Model | ICR mice (6 or 7 weeks, n = 6, male)[1] |
|---|---|
| Dosage | 25 mg/kg |
| Administration | IP, for 4 h, once |
| Result | Reduced blood glucose levels by targeting FBPase and inhibiting the GNG process. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
